Trial · NCT02584634
Adverse events304
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 304
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Group A: Avelumab + Crizotinib | 3 | 12 | |
| other | Anaemia | Blood and lymphatic system disorders | Group B: Avelumab + Lorlatinib | 6 | 31 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Group A: Avelumab + Crizotinib | 1 | 12 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Group B: Avelumab + Lorlatinib | 0 | 31 | |
| other | Atrioventricular block first degree | Cardiac disorders | Group A: Avelumab + Crizotinib | 0 | 12 | |
| other | Atrioventricular block first degree | Cardiac disorders | Group B: Avelumab + Lorlatinib | 2 | 31 | |
| other | Pericardial effusion | Cardiac disorders | Group A: Avelumab + Crizotinib | 1 | 12 | |
| other | Pericardial effusion | Cardiac disorders | Group B: Avelumab + Lorlatinib | 1 | 31 | |
| other | Tinnitus | Ear and labyrinth disorders | Group A: Avelumab + Crizotinib | 1 | 12 | |
| other | Tinnitus | Ear and labyrinth disorders | Group B: Avelumab + Lorlatinib | 1 | 31 | |
| other | Hypothyroidism | Endocrine disorders | Group A: Avelumab + Crizotinib | 0 | 12 | |
| other | Hypothyroidism | Endocrine disorders | Group B: Avelumab + Lorlatinib | 8 | 31 | |
| other | Dry eye | Eye disorders | Group A: Avelumab + Crizotinib | 1 | 12 | |
| other | Dry eye | Eye disorders | Group B: Avelumab + Lorlatinib | 1 | 31 | |
| other | Keratitis | Eye disorders | Group A: Avelumab + Crizotinib | 1 | 12 | |
| other | Keratitis | Eye disorders | Group B: Avelumab + Lorlatinib | 0 | 31 | |
| other | Asthenia | General disorders | Group A: Avelumab + Crizotinib | 2 | 12 | |
| other | Asthenia | General disorders | Group B: Avelumab + Lorlatinib | 3 | 31 | |
| other | Chest pain | General disorders | Group A: Avelumab + Crizotinib | 0 | 12 | |
| other | Chest pain | General disorders | Group B: Avelumab + Lorlatinib | 4 | 31 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02584634/events